GPR82, a receptor that has not been explored within blood cancers but commonlyinvestigated under metabolic diseases thus far, is expressed in lymphoid tissues andbone-marrow-derived dendritic cells.68 A very recent study (2023)suggested a potential ligand for GPR82 called Lysophosphatidylserine.69LysoPS can modulate T cell function by suppressing interleukin-2 production in CD4 Tcells, which could impact the progression of blood cancers, but this requires moreresearch. This evidence concerns the gene CD4 and hematopoietic and lymphoid system neoplasm.